UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Last trade$296.83
Day change-$1.71 (-0.57%)
Day range$294.36 – $306.31
Volume44,571
Market cap$2.31B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.31B
Price / earnings
30.22×
Price / book
4.76×
Price / sales
3.56×
EV / sales
3.68×
EV / EBITDA
19.78×
Profitability
Earnings per share
$9.88
Return on assets
11.21%
Return on equity
15.76%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.2×
Current ratio
2.98×
Quick ratio
1.71×
Cash ratio
0.27×
Cash flow
Price / cash flow
31.17×
Price / free cash flow
36.41×
Free cash flow
$63.51M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for UFPT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$172.43M
$173.96M
$154.2M
$148.92M
$154.56M
$151.18M
$148.15M
$144.07M
Cost of revenue
$121.67M
$123.05M
$109.84M
$106.95M
$111.81M
$107.63M
$106M
$102.01M
Gross profit
$50.76M
$50.92M
$44.36M
$41.97M
$42.75M
$43.54M
$42.15M
$42.06M
Selling, general and administrative
$23.15M
$22.75M
$21.02M
$20.97M
$19.07M
$18.68M
$18.73M
$18.62M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$23.17M
$22.83M
$21.02M
$20.18M
$19.35M
$19.23M
$19.03M
$18.75M
Operating income
$27.6M
$28.09M
$23.34M
$21.79M
$23.4M
$24.32M
$23.13M
$23.31M
Interest expense
-$1.49M
-$1.71M
-$1.74M
-$1.93M
-$2.39M
-$2.67M
-$2.81M
-$3.38M
Income before taxes
$26.12M
$26.43M
$21.61M
$19.54M
$21.06M
$21.63M
$20.28M
$19.1M
Income taxes
$5.5M
$5.58M
$4.11M
$1.98M
$4.68M
$4.45M
$3.1M
$2.72M
Net income
$20.62M
$20.85M
$17.5M
$17.57M
$16.38M
$17.18M
$17.18M
$16.38M
Net income attributable to common shareholders
$20.62M
$20.85M
$17.5M
$17.57M
$16.38M
$17.18M
$17.18M
$16.38M
EBITDA
$32.63M
$33.13M
$28.24M
$26.72M
$28.29M
$29.32M
$27.8M
$28.81M
Basic earnings per share
$2.66
$2.69
$2.27
$2.28
$2.12
$2.23
$2.24
$2.13
Diluted earnings per share
$2.64
$2.68
$2.24
$2.23
$2.11
$2.21
$2.21
$2.08
Recent news
Company coverage with links to the original publishers.
UFP Technologies reported Q3 2026 sales of $172.4 million, up 11.6% year-over-year, with gross margin improving to 29.4%. Medical technology sales grew 12.5% across diverse product lines. However, the company faces temporary margin headwinds from delayed production transfers to the Dominican Republic pending customer qualification. Management maintains a strong balance sheet with leverage under 1x and plans to pursue larger acquisitions while investing in organic growth.
UFP Technologies reported quarterly earnings of $2.88 per share, beating consensus estimates of $2.63 and surpassing revenue expectations. The company has outperformed the S&P 500 by 17.7% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Treace Medical Concepts, a peer in the Medical-Instruments industry, is expected to report a quarterly loss.
UFP Technologies (UFPT) is drawing attention from options traders due to unusually high implied volatility on its October 2026 $200 put options, suggesting market expectations for significant price movement. While the company maintains a Zacks Rank #2 (Buy) rating in the Medical-Instruments sector, analyst sentiment has slightly weakened over the past 60 days, with earnings estimates revised downward from $2.68 to $2.63 per share. Options traders may be positioning to sell premium and capitalize on volatility decay.
UFP Technologies director Cynthia L. Feldmann exercised 1,200 stock options and immediately sold all resulting shares for approximately $287,000 on June 12, 2026. The transaction reduced her direct holdings by 18%, though she maintains 5,476 common shares and 1,282 outstanding options. The sale appears to be a routine compensation-driven liquidity event rather than a bearish signal, as the company continues to execute well with Q1 revenue up 4.1% year-over-year and strong demand in medical device markets.
UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization specializing in single-use and single-patient medical devices, announced that President Mitchell Rock and CFO Ron Lataille will participate in a virtual fireside chat at the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026, at 10:30 AM ET, with opportunities for 1x1 investor meetings.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.